Skip to main content
JW LIFESCIENCE CORPORATION logo

JW LIFESCIENCE CORPORATION — Investor Relations & Filings

Ticker · 234080 ISIN · KR7234080000 KO Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2026-02-02 Earnings Release
Country KR South Korea
Listing KO 234080

About JW LIFESCIENCE CORPORATION

https://www.jw-lifescience.co.kr/lifesc…

JW LIFESCIENCE CORPORATION is a specialized manufacturer focused on the development and production of infusion solutions. The company's product portfolio includes a comprehensive range of intravenous (IV) fluids, from basic solutions to advanced nutrient infusions containing essential components such as amino acids, lipids, proteins, vitamins, and minerals. A key area of innovation is the development of high-value-added products, including multi-chambered infusion solutions. The company operates world-class manufacturing facilities and maintains dedicated research and development centers to support its commitment to producing high-quality medical fluids for patient treatment.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (JW Life Science) announcing a significant change in financial results (30% or more change in revenue or profit structure). This is a standard preliminary earnings announcement required by the Korea Exchange (KRX) for listed companies. It provides key financial highlights (revenue, operating profit, net income) for the fiscal year 2025 compared to 2024. Since it is an initial announcement of financial results rather than a full annual report or a transcript, it falls under the Earnings Release category. FY 2025
2026-02-02 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and the Korea Exchange. It details the acquisition of shares by FIL Limited and its special related parties in JW Life Science Corporation. This type of filing is a standard regulatory requirement for entities crossing significant ownership thresholds (5% rule), which falls under the 'Major Shareholding Notification' category.
2026-01-02 Korean
기타경영사항(자율공시) (배당기준일 변경 안내)
Notice of Dividend Amount Classification · 95% confidence The document is a regulatory filing from JW Life Science regarding a change in the dividend record date policy following an amendment to the company's articles of incorporation. It informs shareholders that the dividend record date will no longer be fixed at December 31st but will be determined by the Board of Directors. Since this is a general regulatory announcement regarding corporate policy and dividend procedures rather than a specific dividend payment announcement (which would include amounts and dates) or a financial report, it falls under the general regulatory filing category.
2025-12-16 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement from JW Life Science regarding the setting of a record date for the upcoming 32nd Annual General Meeting. It is not the AGM presentation itself, nor a proxy statement, but a standard regulatory notice regarding shareholder record dates, which falls under the general regulatory filing category as it does not fit into specific categories like dividend announcements or voting results.
2025-12-16 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled as a provisional (잠정) business performance announcement for JW Life Science covering the period from July 1, 2025 to September 30, 2025. It contains summarized financial figures such as sales, operating profit, and net income for the quarter and cumulative periods, with percentage changes compared to previous periods. The document explicitly states that the figures are provisional and unaudited, and it is a public disclosure (공정공시) intended for investors and media. The length is about 2065 characters, which is relatively short and the document is an announcement of preliminary financial results rather than a full detailed financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Therefore, this document fits best as an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only. Q3 2025
2025-11-05 Korean
[기재정정]분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for JW Life Science, which includes detailed financial statements, management discussion, and notes to the financial statements for the first quarter of 2025. It also contains a section detailing corrections made to the previously submitted report. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. Q1 2025
2025-08-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.